KalVista Pharmaceuticals Statistics
Total Valuation
KALV has a market cap or net worth of $593.11 million. The enterprise value is $345.69 million.
Important Dates
The last earnings date was Wednesday, March 12, 2025, before market open.
| Earnings Date | Mar 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KALV has 49.72 million shares outstanding. The number of shares has increased by 37.13% in one year.
| Current Share Class | 49.72M |
| Shares Outstanding | 49.72M |
| Shares Change (YoY) | +37.13% |
| Shares Change (QoQ) | +12.73% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 71.36% |
| Float | 29.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.07 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.44, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.44 |
| Quick Ratio | 10.25 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -63.84 |
Financial Efficiency
Return on equity (ROE) is -150.50% and return on invested capital (ROIC) is -91.84%.
| Return on Equity (ROE) | -150.50% |
| Return on Assets (ROA) | -58.15% |
| Return on Invested Capital (ROIC) | -91.84% |
| Return on Capital Employed (ROCE) | -72.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, KALV has paid $4.25 million in taxes.
| Income Tax | 4.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.77% in the last 52 weeks. The beta is 0.76, so KALV's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +7.77% |
| 50-Day Moving Average | 10.53 |
| 200-Day Moving Average | 11.11 |
| Relative Strength Index (RSI) | 54.49 |
| Average Volume (20 Days) | 619,269 |
Short Selling Information
The latest short interest is 5.84 million, so 11.74% of the outstanding shares have been sold short.
| Short Interest | 5.84M |
| Short Previous Month | 5.54M |
| Short % of Shares Out | 11.74% |
| Short % of Float | 20.06% |
| Short Ratio (days to cover) | 9.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | -81.07M |
| Operating Income | -181.42M |
| Pretax Income | -126.64M |
| Net Income | -175.87M |
| EBITDA | -180.52M |
| EBIT | -181.42M |
| Earnings Per Share (EPS) | -$3.72 |
Full Income StatementBalance Sheet
The company has $253.20 million in cash and $5.78 million in debt, giving a net cash position of $247.42 million or $4.98 per share.
| Cash & Cash Equivalents | 253.20M |
| Total Debt | 5.78M |
| Net Cash | 247.42M |
| Net Cash Per Share | $4.98 |
| Equity (Book Value) | 145.13M |
| Book Value Per Share | 2.93 |
| Working Capital | 241.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$127.65 million and capital expenditures -$168,000, giving a free cash flow of -$127.82 million.
| Operating Cash Flow | -127.65M |
| Capital Expenditures | -168,000 |
| Free Cash Flow | -127.82M |
| FCF Per Share | -$2.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |